kff employer health benefits survey 2025 glp-1 coverage Among the largest employers (with at least 5,000 workers), 43% now cover GLP -1 weight-loss drugs, up from 28% last year. A majority (59%) of those same employers say their cost for the Summary of the KFF 2025

Those with the SELENOS GA and AA genotypes were significantly more likely to have HT: OR (95 % CI) for HT was 222 (167, 295) and in male A-allele carriers, 394 (143, 1084)

On the flip side, if gastric emptying returns to normal suddenly, absorption might spike, increasing the risk of toxicity

Protective MC4R variants identified in the UK Biobank exhibited signaling bias toward -arrestin recruitment and increased MAPK pathway activation suggesting that -arrestin-biased MC4R signaling may represent an effective strategy for weight loss (109, 110)

[2] Its benefits are best seen when combined with healthy lifestyle habits